Generate report
Aiwell Nordic Aps
Ole Maaløes Vej 3, 2200 København N, CVR 41699094
ad
More financial key figures and analyses?
In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!
Rank Profit for the year
Rank in industry
20/33
"Around avg"
Rank in Denmark
262,071/336,950
"Lowest 35%"
Top management top 3
| Hiroyuki MABUCHI 1 | CEO |
| Yasushi NAKAGAWA 1 | Director |
Legal owners top 3
| 100% | aiwell Inc. | JP |
Rights certificate
Selskabet tegnes af direktørerne i forening.
Company information based on CVR
| Name | Aiwell Nordic Aps |
| CVR | 41699094 |
| Address | Ole Maaløes Vej 3, 2200 København N |
| Industry | Manufacture of basic pharmaceutical products [211000] |
| Established | 23-09-2020 (3 yr) |
| First financial statement period | 23-09-2020 to 31-12-2020 |
| Company type | Limited Corporation (APS) |
| Number of employees | - |
| Advertising protection | No |
| Audit deselected | Yes |
| Financial statement period | 01-01 to 31-12 |
| Company capital | 40,000 DKK |
| Articles of assoc. last | 23-09-2020 |
Member of industries
- Manufacture of basic pharmaceutical productsNACE6 containing 38 comp.
- Manufacture of basic pharmaceutical productsNACE3 containing 38 comp.
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE2 containing 254 comp.
- ManufacturingNACE1 containing 26,560 comp.
Purpose
Selskabets formål er at foreta-ge analytiske test af biologiske prøver. R&D, teknisk træning, forskning på bestilling, import, eksport, fremstilling, konditio-nering og salg af diagnostice-rings-/ testkits, farmaceutiske produkter, kvasi-lægemidler, dyremediciner, antistoffer, en-heder. R&D, drift og vedlige-holdelse af lifescience / biolo-giske datamanagement sy-stemer. Fremstilling, leasing og salg af paramedicinske og medicinsk e apparaturer. R&D inden for avanceret medicinsk teknologi. Samt hermed be-slægtet virksomhed.
Financial Statement
| 2021 | 2020 | |
|---|---|---|
| Currency/unit | 000' DKK | 000' DKK |
| Revenue | - - | - - |
| Gross Profit | -41 - | -20 - |
| Profit for the year | -41 - | -20 - |
| Equity | -21 - | 20 - |
| Total Assets | 19 - | 40 - |
Mangement review
Development in activities and financial matters
The gross loss for the year totals DKK -41.000 against DKK -20.000 last year. Income or loss from ordinary activities after tax totals DKK -41.000 against DKK -20.000 last year. Management considers the net profit or loss for the year satisfactory.
The company has lost more than 50% of the share capital and thus, the company is covered by the rules about capital loss, according to the Danish Companies Act. The management is aware of this and expects a positive development in 2022 and that the share capital be re-established by the company's own operation.
The gross loss for the year totals DKK -41.000 against DKK -20.000 last year. Income or loss from ordinary activities after tax totals DKK -41.000 against DKK -20.000 last year. Management considers the net profit or loss for the year satisfactory.
The company has lost more than 50% of the share capital and thus, the company is covered by the rules about capital loss, according to the Danish Companies Act. The management is aware of this and expects a positive development in 2022 and that the share capital be re-established by the company's own operation.
02-08-2022